

"Publikationsliste 01.09.2021 bis 31.08.2022"

1. [Association of baseline soluble immune checkpoints with the risk of relapse in PR3-ANCA vasculitis following induction of remission.](#) **Amann A**, Gamerith G, Mildner F, Merkel PA, Harris K, Cooney L, Lim N, Spiera R, Seo P, Langford CA, Hoffman GS, St Clair EW, Fervenza FC, Monach P, Ytterberg SR, Geetha D, Wolf D, Specks U, Stone JH, Kronbichler A., *Ann Rheum Dis.* 2022 Aug 16;annrheumdis-2022-222479. doi: 10.1136/ard-2022-222479. Online ahead of print.PMID: 35973802

27.973
2. [Stereotactic radiofrequency ablation of tumors at the hepatic venous confluence.](#) **Amann A**, Schullian P, Johnston E, Laimer G, Scharll Y, Putzer D, Eberle G, Kolbitsch C, Stättner S, Bale R., *HPB (Oxford).* 2022 Jul;24(7):1044-1054. doi: 10.1016/j.hpb.2021.11.010. Epub 2021 Nov 24.PMID: 34887174

3.48
3. [Comprehensive Analysis of R-Spondin Fusions and RNF43 Mutations Implicate Novel Therapeutic Options in Colorectal Cancer.](#) **Amann A, Kocher F**, Seeber A, Battaglin F, Zimmer K, Baca Y, Xiu J, Spizzo G, Novotny-Diermayr V, Rieder D, Puccini A, Swensen J, Ellis M, Goldberg RM, Grothey A, Shields AF, Marshall JL, Weinberg BA, Sackstein PE, Lim KH, Tan GS, Nabhan C, Korn WM, Trajanoski Z, Berger MD, Lou E, Wolf D, Lenz HJ., *Clin Cancer Res.* 2022 May 2;28(9):1863-1870. doi: 10.1158/1078-0432.CCR-21-3018.PMID: 35254413

12.531
4. [Checkpoint inhibitors in metastatic gastric and GEJ cancer: a multi-institutional retrospective analysis of real-world data in a Western cohort.](#) **Amann A, Eisterer W, Wöll E**, Schlintl V, Huemer F, Rinnerthaler G, Melchardt T, Winder T, Reimann P, Riedl J, Romeder F, Piringer G, Ilhan-Mutlu A, Greil R, Weiss L.*BMC Cancer.* 2022 Jan 10;22(1):51. doi: 10.1186/s12885-021-09115-6.PMID: 35012477

4.638
5. [Benefit of second-line therapy for advanced esophageal squamous cell carcinoma: a tri-center propensity score analysis.](#) **Amann A**, Müller M, Posch F, Kiem D, Barth D, Horvath L, Stotz M, Schaberl-Moser R, Pichler M, Greil R, Jost PJ, Seeber A, Schlick K, Gerger A, Riedl JM., *Ther Adv Med Oncol.* 2021 Sep 30;13:17588359211039930. doi: 10.1177/17588359211039930. eCollection 2021.PMID: 34616490

5.485

6. [Deregulated glutamate to pro-collagen conversion is associated with adverse outcome in lung cancer and may be targeted by renin-angiotensin-aldosterone system \(RAS\) inhibition.](#) **Amann A, Kocher F, Pircher A.** Tymoszuk P, Sprung S, Salcher S, Daum S, Haybaeck J, Rinnerthaler G, Huemer F, Kauffmann-Guerrero D, Tufman A, Seeber A, Wolf D, *Lung Cancer*. 2021 Sep; 159:84-95. doi: 10.1016/j.lungcan.2021.06.020. Epub 2021 Jul 16. PMID: 34315093

5.705

7. [Determinants of 25-hydroxyvitamin D Status in a Cutaneous Melanoma Population.](#) **Bechter O,** De Smedt J, Van Kelst S, Janssen L, Marasigan V, Boecxstaens V, Stas M, Vanderschueren D, Guler I, Bogaerts K, Vandenberghe K, Billen J, Nikkels A, Strobbe T, Emri G, Lambrechts D, Garmyn M., *Acta Derm Venereol*. 2022 Apr 8;102:adv00692. doi: 10.2340/actadv.v102.262. PMID: 35312026

4.437

8. [Plexin-A4 Mediates Cytotoxic T-cell Trafficking and Exclusion in Cancer.](#) **Bechter O,** Celus W, Oliveira AI, Rivis S, Van Acker HH, Landeloos E, Serneels J, Cafarello ST, Van Herck Y, Mastrantonio R, Köhler A, Garg AD, Flamand V, Tamagnone L, Marine JC, Di Matteo M, Costa BM, Mazzone M., *Cancer Immunol Res*. 2022 Jan;10(1):126-141. doi: 10.1158/2326-6066.CIR-21-0061. Epub 2021 Nov 23. PMID: 34815265

12.020

9. [Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data.](#) **Bechter O,** Horwitz SM, Scarisbrick JJ, Dummer R, Whittaker S, Duvic M, Kim YH, Quaglino P, Zinzani PL, Eradat H, Pinter-Brown L, Akilov OE, Geskin L, Sanches JA, Ortiz-Romero PL, Weichenthal M, Fisher DC, Walewski J, Trotman J, Taylor K, Dalle S, Stadler R, Lisano J, Bunn V, Little M, Prince HM., *Blood Adv*. 2021 Dec 14;5(23):5098-5106. doi: 10.1182/bloodadvances.2021004710. PMID: 34507350

5.486

10. [Avelumab expanded access program in metastatic Merkel cell carcinoma: Efficacy and safety findings from patients in Europe and the Middle East.](#) **Bechter O,** Ascierto PA, Orlova K, Grignani G, Dudzisz-Śledź M, Fenig E, Chiarion Sileni V, Fazio N, Samimi M, Mortier L, Gebhardt C, Kramkimel N, Steven N, Arance A, Benincasa E, Kostkova L, Costa N, Lorigan P., *Int J Cancer*. 2021 Dec 1;149(11):1926-1934. doi: 10.1002/ijc.33746. Epub 2021 Aug 3. PMID: 34310716

7.316

11. [Is cancer biology different in older patients?](#) **Bechter O**, Van Herck Y, Feyaerts A, Alibhai S, Papamichael D, Decoster L, Lambrechts Y, Pinchuk M, Herrera-Caceres J, Bibeau F, Desmedt C, Hatse S, Wildiers H., *Lancet Healthy Longev.* 2021 Oct;2(10):e663-e677. doi: 10.1016/S2666-7568(21)00179-3. Epub 2021 Sep 29. PMID: 36098020

Keine Punkte speziell für „Lancet Healthy Longevity

12. [Road to Metastasis: The TWEAK Pathway as a Discriminant between Metastasizing and Non-Metastasizing Thick Melanomas.](#) **Bechter O**, Güvenç C, Antoranz A, Szumera-Ciećkiewicz A, Teterycz PP, Rutkowski PR, Rawson RV, Scolyer RA, Thompson JF, Newton-Bishop J, Stas M, Boecxstaens V, Vercauteren J, Garmyn M, van den Oord J, Bosisio FM., *Int J Mol Sci.* 2021 Sep 29;22(19):10568. doi: 10.3390/ijms221910568. PMID: 34638912

6.01

13. [Activation of the integrated stress response confers vulnerability to mitoribosome-targeting antibiotics in melanoma.](#) **Bechter O**, Vendramin R, Katopodi V, Cinque S, Konnova A, Knezevic Z, Adnane S, Verheyden Y, Karras P, Demesmaeker E, Bosisio FM, Kucera L, Rozman J, Gladwyn-Ng I, Rizzotto L, Dassi E, Millevoi S, Marine JC, Leucci E., *J Exp Med.* 2021 Sep 6;218(9):e20210571. doi: 10.1084/jem.20210571. Epub 2021 Jul 21. PMID: 34287642

14.307

14. [New entity of microsecretory adenocarcinoma of salivary glands: first case with recurrence and metastases - proof of malignancy.](#) **Eisterer W**, Jurmeister P, Haas C, Rogatsch H, Ihrler S., *Virchows Arch.* 2022 Jul 2. doi: 10.1007/s00428-022-03374-9. Online ahead of print. PMID: 35780228

4.064

15. [Serologic Responses to COVID-19 Vaccines in Hematological Patients Are Predominantly Impaired in Lymphoid but not in Myeloid Malignancies.](#) **Gunsilius E, Kocher F, Pircher A**, Petzer V, Steiner N, Angelova-Unterberger O, Hetzenauer G, Philipp-Abbrederis K, Willenbacher E, Feistritz C, Willenbacher W, Rudzki J, Stauder R, Seeber A, Tymoszuk P, Isara C, Egger A, Fux V, Anliker M, Nachbaur D, Schmidt S, Wolf D., *Hemasphere.* 2022 Feb 15;6(3):e686. doi: 10.1097/HS9.0000000000000686. eCollection 2022 Mar. PMID: 35187405

8.3

16. [Increased levels of NETosis in myeloproliferative neoplasms are not linked to thrombotic events.](#) **Gunsilius E**, Schmidt S, Danilants D, Hiller E, Wolf D, Feistritz C., *Blood Adv.* 2021 Sep 28;5(18):3515-3527. doi: 10.1182/bloodadvances.2020004061. PMID: 34464975

7.367

17. [Sustained Complete Remission in Multi-Relapsed Primary CNS Lymphoma Treated with Ibrutinib Monotherapy: A Case Report.](#) **Gunsilius E.**, Mair A, Muigg A, Stockhammer G, Mangesius S, Wolf D, Case Rep Oncol. 2021 Sep 20;14(3):1337-1341. doi: 10.1159/000518528. eCollection 2021 Sep-Dec.PMID: 34720938

1.143

18. [COVID-19 crisis and cancer.](#) **Hilbe W.**, Bartsch R, Memo. 2022;15(2):98-99. doi: 10.1007/s12254-022-00812-x. Epub 2022 Jun 7.PMID: 35693202

0.535

19. [High SARS-CoV-2 vaccination coverage but still room for improvement in patients with haemophilia: A single-centre analysis.](#) **Kocher F**, Seeber A, Fauser J, Petzer V, Wolf D, Feistritz C., Haemophilia. 2022 Mar;28(2):e71-e72. doi: 10.1111/hae.14500. Epub 2022 Feb 1.PMID: 35106872

4.287

20. [The DNA damage repair-related gene *PKMYT1* is a potential biomarker in various malignancies.](#) **Kocher F**, Shao C, Wang Y, Pan M, Guo K, Molnar TF, Seeber A, Barr MP, Navarro A, Han J, Ma Z, Yan X., Transl Lung Cancer Res. 2021 Dec;10(12):4600-4616. doi: 10.21037/tlcr-21-973.PMID: 35070764

4.726

21. [Correlations between peripheral blood biomarkers and clinical outcomes in advanced non-small cell lung cancer patients who received immunotherapy-based treatments.](#) **Kocher F**, Shi Y, Liu X, Liu J, Zhang D, Liu X, Yue Y, Zhou Q, Gao X, Chen M, Xu Y, Zhao J, Zhong W, Provencio M, Jassem J, Williams TM, Seeber A, Wang M., Transl Lung Cancer Res. 2021 Dec;10(12):4477-4493. doi: 10.21037/tlcr-21-710.PMID: 35070755

4.726

22. [Real-world experience with anti-PD-1/PD-L1 monotherapy in patients with non-small cell lung cancer : A retrospective Austrian multicenter study.](#) **Kocher F, Pall G.**, Geiger-Gritsch S, Olschewski H, Wurm R, Absenger G, Flicker M, Hermann A, Heining P, Fiegl M, Zechmeister M, Endel F, Wild C, Wien Klin Wochenschr. 2021 Nov;133(21-22):1122-1130. doi: 10.1007/s00508-021-01940-w. Epub 2021 Sep 15.PMID: 34528126

1.604

23. [Targeting BRCA and DNA Damage Repair Genes in GI Cancers: Pathophysiology and Clinical Perspectives](#). Kocher F, Zimmer K, Puccini A, Seeber A., *Front Oncol.* 2021 Oct 11;11:662055. doi: 10.3389/fonc.2021.662055. eCollection 2021.PMID: 34707985

6.244

24. [Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer \(RECAP\): a retrospective analysis from an early access program](#). Pall G, Illini O, Fabikan H, Swalduz A, Vikström A, Krenbek D, Schumacher M, Dudnik E, Studnicka M, Öhman R, Wurm R, Wannesson L, Peled N, Kian W, Bar J, Daher S, Addeo A, Rotem O, Zer A, Saad A, Cufer T, Sorotsky HG, Hashemi SMS, Mohorcic K, Stoff R, Rovitsky Y, Keren-Rosenberg S, Winder T, Weinlinger C, Valipour A, Hochmair MJ., *Ther Adv Med Oncol.* 2022 Jun 13;14:17588359221103206. doi: 10.1177/17588359221103206. eCollection 2022.PMID: 35720834

5.02

25. [Comprehensive characterization of the prostate tumor microenvironment identifies CXCR4/CXCL12 crosstalk as a novel antiangiogenic therapeutic target in prostate cancer](#). Pircher A., Heidegger I, Fotakis G, Offermann A, Goveia J, Daum S, Salcher S, Noureen A, Timmer-Bosscha H, Schäfer G, Walenkamp A, Perner S, Beatovic A, Moisse M, Plattner C, Krogsdam A, Haybaeck J, Sopper S, Thaler S, Keller MA, Klocker H, Trajanoski Z, Wolf D, *Mol Cancer.* 2022 Jun 18;21(1):132. doi: 10.1186/s12943-022-01597-7.PMID: 35717322

35.68

26. [Re: Qing Cheng, William Butler, Yinglu Zhou, et al. Pre-existing Castration-resistant Prostate Cancer-like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy](#). *Eur Urol.* 2022;81:446-55. Pircher A., Heidegger I, *Eur Urol.* 2022 Jun;81(6):e145. doi: 10.1016/j.eururo.2022.02.025. Epub 2022 Mar 11.PMID: 35287980

20.096

27. [Biomarkers to personalize treatment with 177Lu-PSMA-617 in men with metastatic castration-resistant prostate cancer - a state of the art review](#). Pircher A, Heidegger I, Kesch C, Kretschmer A, Tsaour I, Ceci F, Valerio M, Tilki D, Marra G, Preisser F, Fankhauser CD, Zattoni F, Chiu P, Puche-Sanz I, Olivier J, van den Bergh RCN, Kasivisvanathan V, Virgolini I, Gandaglia G., *Ther Adv Med Oncol.* 2022 Mar 5;14:17588359221081922. doi: 10.1177/17588359221081922. eCollection 2022.PMID: 35273651

8.168

28. [Hairy Cell Leukemia Patients Have a Normal Life Expectancy-A 35-Year Single-Center Experience and Comparison with the General Population.](#) Pircher A, Bohn JP, Neururer S, Pirklbauer M, Wolf D., *Cancers (Basel)*. 2022 Feb 28;14(5):1242. doi: 10.3390/cancers14051242.PMID: 35267550

6.575

29. [A small ribosome-associated ncRNA globally inhibits translation by restricting ribosome dynamics.](#) Pircher A, Reuther J, Schneider L, Iacovache I, Gharib WH, Zuber B, Polacek N., *RNA Biol*. 2021 Dec;18(12):2617-2632. doi: 10.1080/15476286.2021.1935573. Epub 2021 Jun 13.PMID: 34121604

4.652

30. [A Systematic Review of the Emerging Role of Immune Checkpoint Inhibitors in Metastatic Castration-resistant Prostate Cancer: Will Combination Strategies Improve Efficacy?](#) Pircher A, Heidegger I, Necchi ATsaur I, Marra G, Kasivisvanathan V, Kretschmer A, Mathieu R, Ceci F, van den Bergh RCN, Thibault C, Tilki D, Valerio M, Surcel C, Gandaglia G; EAU-YAU Prostate Cancer Working Party. *Eur Urol Oncol*. 2021 Oct;4(5):745-754. doi: 10.1016/j.euo.2020.10.010. Epub 2020 Nov 23.PMID: 33243663

8.208

31. [Differential procoagulatory response of microvascular, arterial and venous endothelial cells upon inflammation in vitro.](#) Pircher A, Brandtner AK, Lehner GF, Feistritz C, Joannidis M., *Thromb Res*. 2021 Sep;205:70-80. doi: 10.1016/j.thromres.2021.07.002. Epub 2021 Jul 2.PMID: 3426560

10.407

32. [Real-World Evaluation of Quality of Life, Effectiveness, and Safety of Aflibercept Plus FOLFIRI in Patients with Metastatic Colorectal Cancer: The Prospective QoLiTrap Study.](#) Thaler J, Hofheinz RD, Anchisi S, Grünberger B, Derigs HG, Zahn MO, Geffriaud-Ricouard C, Gueldner M, Windemuth-Kieselbach C, Pederiva S, Bohanes P, Scholten F, Piringer G, von Moos R., *Cancers (Basel)*. 2022 Jul 20;14(14):3522. doi: 10.3390/cancers14143522.PMID: 35884583

6.575

33. [Chest CT of Lung Injury 1 Year after COVID-19 Pneumonia: The CovILD Study.](#) Wöll E, Luger AK, Sonnweber T, Gruber L, Schwabl C, Cima K, Tymoszek P, Gerstner AK, Pizzini A, Sahanic S, Boehm A, Coen M, Stolz CJ, Weiss G, Kirchmair R, Feuchtnner GM, Prosch H, Tancevski I, Löffler-Ragg J, Widmann G., *Radiology*. 2022 Aug;304(2):462-470. doi: 10.1148/radiol.211670. Epub 2022 Mar 29.PMID: 35348379

29.146

34. ["Beyond the guidelines" - Deviations in adherence to infection control measures in Tyrolean hospitals, Austria.](#) Wöll E, Berktold M, Fuchs S, Kuppelwieser B, Ulmer H, Kettner M, Thummer

L, Lass-Flörl C; Study Group Hygiene Tyrol., Am J Infect Control. 2022 Jul 20:S0196-6553(22)00545-4. doi: 10.1016/j.ajic.2022.07.005. Online ahead of print.PMID: 35870661

3.55

35. [The Impact of Iron Dyshomeostasis and Anaemia on Long-Term Pulmonary Recovery and Persisting Symptom Burden after COVID-19: A Prospective Observational Cohort Study.](#) **Wöll E**, onnweber T, Grubwieser P, Sahanic S, Böhm AK, Pizzini A, Luger A, Schwabl C, Koppelstätter S, Kurz K, Puchner B, Sperner-Unterweger B, Hufner K, Nairz M, Widmann G, Tancevski I, Löffler-Ragg J, Weiss G., Metabolites. 2022 Jun 14;12(6):546. doi: 10.3390/metabo12060546.PMID: 35736479

4.754

36. [Investigating phenotypes of pulmonary COVID-19 recovery: A longitudinal observational prospective multicenter trial.](#) **Wöll E**, Sonnweber T, Tymoszuk P, Sahanic S, Boehm A, Pizzini A, Luger A, Schwabl C, Nairz M, Grubwieser P, Kurz K, Koppelstätter S, Aichner M, Puchner B, Egger A, Hoermann G, Weiss G, Widmann G, Tancevski I, Löffler-Ragg J., Elife. 2022 Feb 8;11:e72500. doi: 10.7554/eLife.72500.PMID: 35131031

8.713

37. [Muscle involvement in SARS-CoV-2 infection.](#) **Wöll E**, Pitscheider L, Karolyi M, Burkert FR, Helbok R, Wanschitz JV, Horlings C, Pawelka E, Omid S, Traugott M, Seitz T, Zoufaly A, Lindeck-Pozza E, Beer R, Seiwald S, Bellmann-Weiler R, Hegen H, Löscher WN., Eur J Neurol. 2021 Oct;28(10):3411-3417. doi: 10.1111/ene.14564. Epub 2020 Oct 25.PMID: 32997370

6.288

38. [Prior Vaccination Exceeds Prior Infection in Eliciting Innate and Humoral Immune Responses in Omicron Infected Outpatients.](#) **Zabernigg A**, Lee HK, Knabl L, Walter M, Knabl L Sr, Dai Y, Füßl M, Caf Y, Jeller C, Knabl P, Obermoser M, Baurecht C, Kaiser N, Wurdinger GM, Furth PA, Hennighausen L., Front Immunol. 2022 Jun 15;13:916686. doi: 10.3389/fimmu.2022.916686. eCollection 2022.PMID: 35784346

7.561

39. [Immune transcriptome analysis of COVID-19 patients infected with SARS-CoV-2 variants carrying the E484K escape mutation identifies a distinct gene module.](#) **Zabernigg A**, Lee HK, Knabl L, Knabl L Sr, Wieser M, Mur A, Schumacher J, Kapferer S, Kaiser N, Furth PA, Hennighausen L., Sci Rep. 2022 Feb 18;12(1):2784. doi: 10.1038/s41598-022-06752-0.PMID: 35181735

4.996

40. [BNT162b2 vaccination enhances interferon-JAK-STAT-regulated antiviral programs in COVID-19 patients infected with the SARS-CoV-2 Beta variant.](#) **Zabernigg A**, Knabl L, Lee HK, Wieser M, Mur

A, Knabl L Sr, Rauch S, Bock M, Schumacher J, Kaiser N, Furth PA, Hennighausen L., *Commun Med (Lond)*. 2022;2(1):17. doi: 10.1038/s43856-022-00083-x. Epub 2022 Feb 22. PMID: 35465056

0.064

41. [Landscape of HER2-low metastatic breast cancer \(MBC\): results from the Austrian AGMT MBC-Registry](#). **Zabernigg AF**, Gampenrieder SP, Rinnerthaler G, Tinchon C, Petzer A, Balic M, Heibl S, Schmitt C, Egle D, Sandholzer M, Singer CF, Roitner F, Hager C, Andel J, Hubalek M, Knauer M, Greil R., *Breast Cancer Res*. 2021 Dec 14;23(1):112. doi: 10.1186/s13058-021-01492-x. PMID: 34906198

6.466

GESAMT: 329.303 Punkte